Janney Montgomery Scott LLC Has $271,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Janney Montgomery Scott LLC decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 12.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,876 shares of the company’s stock after selling 966 shares during the period. Janney Montgomery Scott LLC’s holdings in CRISPR Therapeutics were worth $271,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of CRSP. State Street Corp increased its position in shares of CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares during the period. FMR LLC increased its holdings in CRISPR Therapeutics by 1.0% in the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after buying an additional 23,075 shares during the period. Geode Capital Management LLC raised its stake in shares of CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after buying an additional 35,196 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of CRISPR Therapeutics by 743.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after acquiring an additional 743,075 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of CRISPR Therapeutics by 0.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company’s stock valued at $34,025,000 after acquiring an additional 6,635 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Up 0.5 %

CRISPR Therapeutics stock opened at $39.62 on Wednesday. The business’s 50-day simple moving average is $42.45 and its 200 day simple moving average is $46.40. The stock has a market cap of $3.38 billion, a price-to-earnings ratio of -14.00 and a beta of 1.67. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CRSP. Barclays cut their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Chardan Capital reiterated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Bank of America cut their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $77.59.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.